File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Chronic viral hepatitis in hemodialysis patients

TitleChronic viral hepatitis in hemodialysis patients
Authors
KeywordsChronic hepatitis
Epidemiology
Infection control
Treatment
Issue Date2005
PublisherBlackwell Publishing, Inc. The Journal's web site is located at http://www.blackwellpublishing.com/journals/HDI
Citation
Hemodialysis International, 2005, v. 9 n. 2, p. 169-179 How to Cite?
AbstractEver since the first outbreaks of hepatitis in hemodialysis units in the late 1960s, a number of hepatotropic viruses transmitted by blood and other body fluids have been identified. This review summarizes the current state of knowledge regarding these blood-borne agents from an epedemiologic and preventive perspective. Data source and study selection were obtained from research and review articles related to the epidemiology of viral hepatitis in hemodialysis and indexed on Medline and Embase from 1965 to 2004. Hepatitis B virus (HBV) was the first significant hepatotropic virus to be identified in hemodialysis centers. HBV infection has been effectively controlled by active vaccination, screening of blood donors, the use of erythropoietin, and segregation of HBV carriers. To date, HBV remains an important cause of morbidity in endemic areas. Hepatitis delta virus is a defective virus that can only infect HBV-positive individuals. Hepatitis C virus is the most significant cause of non-A, non-B hepatitis and is mainly transmitted by blood transfusion. The introduction in 1990 of routine screening of blood donors for HCV contributed significantly to the control of HCV transmission. An effective HCV vaccine remains an unsolved challenge, however. Pegylation of interferon-α has made it possible to treat HCV-positive dialysis patients. Unexplained sporadic outbreaks of hepatitis by the mid-1990s prompted the discovery of hepatitis G virus and hepatitis GB virus C in 1995 and the TT virus in 1997. Although epidemiologic analyses revealed high prevalence rates of both viruses in the hemodialysis population, their exact role in liver disease has yet to be determined. The vigilant observation of guidelines on universal precaution and regular virologic testing are the cornerstones of the effective control of chronic hepatitis in the setting of hemodialysis. © 2005 International Society for Hemodialysis.
Persistent Identifierhttp://hdl.handle.net/10722/77115
ISSN
2015 Impact Factor: 1.495
2015 SCImago Journal Rankings: 0.568
References

 

DC FieldValueLanguage
dc.contributor.authorTang, Sen_HK
dc.contributor.authorLai, KNen_HK
dc.date.accessioned2010-09-06T07:28:25Z-
dc.date.available2010-09-06T07:28:25Z-
dc.date.issued2005en_HK
dc.identifier.citationHemodialysis International, 2005, v. 9 n. 2, p. 169-179en_HK
dc.identifier.issn1492-7535en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77115-
dc.description.abstractEver since the first outbreaks of hepatitis in hemodialysis units in the late 1960s, a number of hepatotropic viruses transmitted by blood and other body fluids have been identified. This review summarizes the current state of knowledge regarding these blood-borne agents from an epedemiologic and preventive perspective. Data source and study selection were obtained from research and review articles related to the epidemiology of viral hepatitis in hemodialysis and indexed on Medline and Embase from 1965 to 2004. Hepatitis B virus (HBV) was the first significant hepatotropic virus to be identified in hemodialysis centers. HBV infection has been effectively controlled by active vaccination, screening of blood donors, the use of erythropoietin, and segregation of HBV carriers. To date, HBV remains an important cause of morbidity in endemic areas. Hepatitis delta virus is a defective virus that can only infect HBV-positive individuals. Hepatitis C virus is the most significant cause of non-A, non-B hepatitis and is mainly transmitted by blood transfusion. The introduction in 1990 of routine screening of blood donors for HCV contributed significantly to the control of HCV transmission. An effective HCV vaccine remains an unsolved challenge, however. Pegylation of interferon-α has made it possible to treat HCV-positive dialysis patients. Unexplained sporadic outbreaks of hepatitis by the mid-1990s prompted the discovery of hepatitis G virus and hepatitis GB virus C in 1995 and the TT virus in 1997. Although epidemiologic analyses revealed high prevalence rates of both viruses in the hemodialysis population, their exact role in liver disease has yet to be determined. The vigilant observation of guidelines on universal precaution and regular virologic testing are the cornerstones of the effective control of chronic hepatitis in the setting of hemodialysis. © 2005 International Society for Hemodialysis.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing, Inc. The Journal's web site is located at http://www.blackwellpublishing.com/journals/HDIen_HK
dc.relation.ispartofHemodialysis Internationalen_HK
dc.subjectChronic hepatitisen_HK
dc.subjectEpidemiologyen_HK
dc.subjectInfection controlen_HK
dc.subjectTreatmenten_HK
dc.subject.meshAntiviral Agents - therapeutic useen_HK
dc.subject.meshChronic Diseaseen_HK
dc.subject.meshHepatitis, Viral, Human - epidemiology - etiology - prevention & control - therapyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshKidney Failure, Chronic - complications - therapyen_HK
dc.subject.meshRenal Dialysis - adverse effectsen_HK
dc.subject.meshViral Hepatitis Vaccines - therapeutic useen_HK
dc.titleChronic viral hepatitis in hemodialysis patientsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1492-7535&volume=9&spage=169&epage=179&date=2005&atitle=Chronic+viral+hepatitis+in+hemodialysis+patientsen_HK
dc.identifier.emailTang, S: scwtang@hku.hken_HK
dc.identifier.emailLai, KN: knlai@hku.hken_HK
dc.identifier.authorityTang, S=rp00480en_HK
dc.identifier.authorityLai, KN=rp00324en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1492-7535.2005.01129.xen_HK
dc.identifier.pmid16191066-
dc.identifier.scopuseid_2-s2.0-21644485818en_HK
dc.identifier.hkuros100098en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-21644485818&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume9en_HK
dc.identifier.issue2en_HK
dc.identifier.spage169en_HK
dc.identifier.epage179en_HK
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridTang, S=7403437082en_HK
dc.identifier.scopusauthoridLai, KN=7402135706en_HK
dc.identifier.citeulike145362-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats